Carrimycin, a first in-class anti-cancer agent, targets selenoprotein H to induce nucleolar oxidative stress and inhibit ribosome biogenesis

Carrimycin is a synthetic macrolide antibiotic that has been shown to have anti-cancer activity; however, its exact mechanism of action and molecular target were previously unknown. It was recently elucidated that Isovalerylspiramycin I (ISP I), the active component of carrimycin, targets selenoprot...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, LaYow C., Dang, Danielle D., Zhuang, Sophie, Chen, Shuran, Zhuang, Zhengping, Rosenblum, Jared S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518895/
https://www.ncbi.nlm.nih.gov/pubmed/37750087
http://dx.doi.org/10.1016/j.cpt.2022.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518895/
https://www.ncbi.nlm.nih.gov/pubmed/37750087
http://dx.doi.org/10.1016/j.cpt.2022.12.005

Ejemplares similares